Feedback

Prof. Gaikwad Anil Bhanudas

Professor, Department of Pharmacy,
BITS Pilani, Pilani Campus

Pharmacology
Department of Pharmacy, Birla Institute of Technology & Science, Pilani- 333031, Rajasthan. India.

Book Chapters

 

  • Sharma N, Shiva N, Kulkarni YA, and Gaikwad AB (2022), Role of Histone Modifications in the Development of Acute Kidney Injury. Epigenetics in Organ Specific Disorders. Elsevier. Chapter 19. 
  • Malek V, Suryavanshi SV, Sharma N, YA Kulkarni, Mulay SR, and Gaikwad AB (2021) Potential of Renin-Angiotensin-Aldosterone 5 System Modulations in Diabetic Kidney Disease: Old Players to New Hope!. Reviews of Physiology, Biochemistry & Pharmacology 179, Pages 31-71. [Impact Factor: 7]
  • A Laddha, K Adki, M. J. Oza, Gaikwad AB and YA Kulkarni (2020) Medicinal Plants from Genus Costus in the Management of Diabetes. Phytotherapy in the Management of Diabetes and Hypertension, Bentham Science. Chapter 4, Pages 110-118.
  • A Laddha, Gaikwad AB and Kulkarni YA (2021) Structural and functional insights of VEGF and its receptors. Encyclopedia of Biological Chemistry III (Third Edition), Volume 6, 2021, Pages 286-293, Elsevier, USA.
  • K Adki, A Laddha, M. J. Oza,  Gaikwad AB and YA Kulkarni (2020) Terpenes and Terpenoids In Management of Diabetes & Cardiovascular Diseases. Phytotherapy in the Management of Diabetes and Hypertension, Bentham Science. Chapter 5, Volume 4, Pages 127-165.
  • KM Adki, AP Laddha, Gaikwad AB, YA Kulkarni (2020) Potential Role of Seeds from India in Diabetes. In: Nuts and Seeds in Health and Disease Prevention. Second Edition Academic Press: Elsevier, USA. 2020, Chapter 26, Pages 365-391.
  • AP Laddha, KM Adki, Gaikwad AB,YA Kulkarni (2020) Beneficial Effects of Nuts From India in Cardiovascular Disorders. In: Nuts and Seeds in Health and Disease Prevention. Second Edition Academic Press: Elsevier, USA, Chapter 32, Pages 453-469.
  • M.J. Oza, M.S. Garud, Gaikwad AB, YA Kulkarni (2017) Fibromyalgia Syndrome: Role of Obesity and Nutrients. In: Nutrition and Functional Foods for Healthy Aging. Academic Press: Elsevier, USA. Pages 53-59.
  • N. Sharma, Gaikwad AB, YA Kulkarni (2017) Folic Acid in Pain: An Epigenetic Link. In: Nutritional Modulators of Pain in the Aging Population. Academic Press: Elsevier, USA. Pages 245-251.
  • Y.A. Kulkarni, S.V. Suryavanshi, S.T. Auti, Gaikwad AB (2017) Capsicum: A Natural Pain Modulator. In: Nutritional Modulators of Pain in the Aging Population. Academic Press: Elsevier, USA. Pages 107-118.
  • M.S. Garud, M.J. Oza, Gaikwad AB, YA Kulkarni (2017) Natural Remedies for Treatment of Cancer Pain. In: Nutritional Modulators of Pain in the Aging Population. Academic Press: Elsevier, USA. Pages 101-106.
  • Y.A. Kulkarni, M.S. Garud, M.J. Oza, Gaikwad AB (2017) Biomarkers of Multiple Sclerosis and Their Modulation by Natural Products. Nutrition and Lifestyle. In: Neurological Autoimmune Diseases: Multiple Sclerosis. Academic Press: Elsevier, USA. Pages 275-284.
  • Y.A. Kulkarni, M.S. Garud, M.J. Oza, Barve K H., Gaikwad AB,  (2016) Diabetes, diabetic complications, and flavonoids. In: Fruits, Vegetables, and Herbs. Academic Press: Elsevier, USA. Pages.77-104.
  • Y.A. Kulkarni, M.S. Garud, Gaud R.S., Gaikwad AB, (2016) Recent developments in using plant-derived natural products as tubulin inhibitors for the management of cancer. In: Fruits, Vegetables, and Herbs. Academic Press: Elsevier, USA. Pages 507-524.
  • Barve K H., Y.A. Kulkarni, Gaikwad AB (2016) Nutraceuticals as therapeutic agents for inflammation. In: Fruits, Vegetables, and Herbs. Academic Press: Elsevier, USA. Pages 121-147.
  • Pandey A, Y.A. Kulkarni, Gaikwad AB, (2016) Curcumin: The epigenetic therapy. In: Fruits, Vegetables, and Herbs. Academic Press: Elsevier, USA. Pages 105-119.

Review Articles

 

  • Saxena S, Dagar N, Shelke V, Lech M, Khare P, Gaikwad AB (2023). Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease. Drug Discovery Today. 28(11):103765. DOI: 10.1016/j.drudis.2023.103765. [Impact factor: 7.4]
  • Shelke V, Yelgonde V, Kale A, Lech M, Gaikwad AB (2023). Epigenetic regulation of mitochondrial‐endoplasmic reticulum dynamics in kidney diseases. Journal of Cellular Physiology,  DOI:10.1002/jcp.31058. [Impact factor: 5.6]
  • Dagar N, Kale A, Jadhav HR, Gaikwad AB (2023). Nutraceuticals and network pharmacology approach for acute kidney injury: A review from the drug discovery aspect. Fitoterapia. 168, 105563, [Impact factor: 3.4]
  • Habshi T, Shelke V, Kale A, Lech M, Gaikwad AB (2023). Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets. Drug Discovery Today.28(8).103649. [Impact factor: 7.4]
  • Kale A, Lech M, Anders HJ, Gaikwad AB (2023), Lupus Nephritis: New and Emerging Biologic and Targeted Therapies. BioDrugs. doi: 10.1007/s40259-023-00597-3. [Impact factor: 6.8]
  • Akhouri V, Majumder S, Gaikwad AB (2023), The emerging insight into E3 ligases as the potential therapeutic target for diabetic kidney disease. Life Sciences 321:121643 [Impact factor: 6.1]
  • Kale A, Shelke V, Dagar N, Anders HJ, Gaikwad AB (2023), How to use COVID-19 antiviral drugs in patients with chronic kidney disease. Frontiers in Pharmacology, 14, DOI: 10.3389/fphar.2023.1053814. [Impact factor: 5.6]
  • Shelke V, Kale A, Anders HJ, Gaikwad AB (2022), Toll-like receptors 2 and 4 stress signaling and sodium-glucose cotransporter-2 in kidney disease. Molecular and Cellular Biochemistry, DOI: 10.1007/s11010-022-04652-5. [Impact factor: 4.3]
  • Tejeswini Sen T, Kale A, Lech M, Anders HJ, Gaikwad AB (2023), Promising novel therapeutic targets for kidney disease: Emphasis on kidney-specific proteins, Drug Discovery Today, 9;28(2):103466. DOI: 10.1016/j.drudis.2022.103466.[Impact factor: 7.4]
  • Habshi T, Shelke V, Kale A, Anders HJ, Gaikwad AB (2023), Role of endoplasmic reticulum stress and autophagy in the transition from acute kidney injury to chronic kidney disease, Journal of Cellular Physiology, 238(1):82-93. [Impact factor: 5.6]
  • Dagar N, Kale A, Steiger S, Anders HJ, Gaikwad AB (2022), Receptor-mediated mitophagy: An emerging therapeutic target in acute kidney injury, Mitochondrion, Volume 66, 2022, Pages 82-91. [Impact factor: 4.4]
  • Kale A, Sharma A, Anders HJ, Gaikwad AB (2022) Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors. Current Diabetes Reviews DOI: 10.2174/1573399819666220816145907. 
  • Shelke V, Kale A, Anders HJ, Gaikwad AB (2022) Epigenetic regulation of Toll-like receptors 2 and 4 in kidney disease. Journal of Molecular Medicine 7:1017-1026 [Impact factor: 4.7]
  • Sankrityayan H, Rao PD, Shelke V, Kulkarni YA, Mulay SR, Gaikwad AB (2023) Endoplasmic Reticulum Stress and Renin-Angiotensin System Crosstalk in Endothelial Dysfunction. Current Molecular Pharmacology 16(2):139-146 [Impact factor: 2.7]
  • Shelke V, Kale A, Sankrityayan H, Anders HJ, Gaikwad AB (2022) Long non-coding RNAs as emerging regulators of miRNAs and epigenetics in diabetes-related chronic kidney disease. Archives of Physiology and Biochemistry 5:1-12 [Impact factor: 3.0]
  • Kale A, Sankrityayan H, Anders HJ, Gaikwad AB (2023) Klotho in kidney diseases: A crosstalk between the renin-angiotensin system and endoplasmic reticulum stress. Nephrology Dialysis Transplantation 38(4):819-825 [Impact factor: 6.1]
  • Sharma N, Sircar A, Anders HJ, Gaikwad AB. (2022) Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches. Archives of Physiology and Biochemistry 128(4):1024-1038 [Impact factor: 3.0]
  • Oza MJ, Laddha AP, Gaikwad AB, Mulay SR, Kulkarni YA (2021) Role of dietary modifications in the management of type 2 diabetic complications. Pharmacological Research 168:105602 [Impact factor: 9.3]
  • Kale A, Sankrityayan H, Anders HJ, Gaikwad AB (2021) Klotho: A possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes. Drug Discovery Today 26:1963-1971 [Impact factor: 7.4]
  • Srivastava A, Tomar B, Prajapati S, Gaikwad AB, Mulay SR (2021) Advanced non-invasive diagnostic techniques for visualization and estimation of kidney fibrosis. Drug Discovery Today 26:2053-2063 [Impact factor: 7.4]
  • Kale A, Sankrityayan H, Anders HJ, Gaikwad AB. (2021) Epigenetic and non-epigenetic regulation of Klotho in kidney disease. Life Sciences 264:118644 [Impact factor: 6.1]
  • Shiva N, Sharma N, Kulkarni YA, Mulay SR, Gaikwad AB. (2020) Renal ischemia/reperfusion injury: An insight on in vitro and in vivo models.  Life Sciences 256:117860.[Impact factor: 6.1]
  • Sankrityayan H, Kale A, Sharma N, Anders HJ, Gaikwad AB. (2020) Evidence for Use or Disuse of Renin-Angiotensin System Modulators in Patients Having COVID-19 With an Underlying Cardiorenal Disorder. Journal of Cardiovascular Pharmacology and Therapeutics 25(4):299-306. [Impact factor: 2.6]
  • Rao PD, Sankrityayan H, Srivastava A, Kulkarni YA, Mulay SR, Gaikwad AB. (2020) 'PARP'ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors. Drug Discovery Today 25(7):1253-1261. [Impact factor: 7.4]
  • Sankrityayan H, Oza MJ, Kulkarni YA, Mulay SR, Gaikwad AB., (2019) ER stress response mediates diabetic microvascular complications. Drug Discovery Today . 24(12) 2247-2257. [Impact factor: 7.4]
  • Sankrityayan H, Kulkarni YA, Gaikwad AB. (2019) Diabetic Nephropathy: the regulatory interplay between Epigenetics and microRNAs. Pharmacological Research 141:574-585. [Impact factor: 9.3]
  • Sharma N, Anders HJ, Gaikwad AB. (2019) Fiend and friend in the renin angiotensin system: An insight on acute kidney injury. Biomedicine & Pharmacotherapy 110:764-774. [Impact factor: 7.5]
  • Pandey A and Gaikwad AB. (2017) AT2 receptor agonist Compound 21: A silver lining for diabetic nephropathy. European Journal of Pharmacology 95:1461-1468. [Impact factor: 5.0]
  • Malek V, Gaikwad AB. (2017) Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications? Biomedicine & Pharmacotherapy 90:752-759 [Impact Factor: 7.5]
  • Goru SK, Kadakol A, Gaikwad AB. (2017) Hidden targets of ubiquitin proteasome system: To prevent diabetic nephropathy. Pharmacological Research 120: 170-179 [Impact Factor: 9.3]
  • Kadakol A, Sharma N, Kulkarni YA, Gaikwad AB (2016) Esculetin: A phytochemical endeavor fortifying effect against non-communicable diseases. Biomedicine & Pharmacotherapy 84: 1442-1448 [Impact Factor: 7.5]
  • Goru SK, Pandey A, Gaikwad AB. (2016) E3 ubquitin ligases as novel therapuetic targets for inflammatory diseases. Pharmacological Research 106: 1–9 [Impact Factor: 9.3]
  • Pandey A, Kumar GS, Kadakol A, Malek V, Gaikwad AB. (2016) FoxO1 inhibitors: The future medicine for metabolic disorders? Current Diabetes Reviews 12:1-8. 
  • Pandey A, Malek V, Prabhakar V, Kulkarni YA, and Gaikwad AB. (2015) Nanoparticles and Neurotoxicity: A Mechanistic Approach. CNS & Neurological Disorders - Drug Targets. 14(10):1317-27.  [Impact Factor: 2.824]
  • Kumar P, Kadakol  AM, Prashanth KS, Nitin AM, Vinayak SJ, Baruad CC and Gaikwad AB, (2015) Curcumin as an adjuvant to breast cancer treatment. Anti-Cancer Agents in Medicinal Chemistry 15(6), 647-656. [Impact Factor: 2.8]
  • Pandey A, Pooja M, Chandak PG and Gaikwad AB. (2014) PARG Inhibitors Success: A Long Way To Go! Current Enzyme Inhibition. 10 (2), 81-93.
  • Woroniecki R, Gaikwad AB, Susztak K (2011) Fetal environment, epigenetics, and pediatric renal disease. Pediatric Nephrology 26(5): 705- 711. [Impact Factor: 3.0] 

 

Other review articles

 

  • Kale A., Gaikwad AB (2022), Klotho: A hope for acute kidney injury-diabetes comorbidity.

Publications

 

Details of Citations

 

View Citations

 

Research Articles

  • Kale A, Shelke V, Habshi T, Dagar N, Gaikwad AB. (2023) Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2:166905. DOI: 10.1016/j.bbadis.2023.166905. [Impact factor: 6.2]
  • Shelke V, Dagar N, Gaikwad AB. (2023) Phloretin as an add-on therapy to losartan attenuates diabetes-induced AKI in rats: A potential therapeutic approach targeting TLR4-induced inflammation. Life Sciences. 332, 122095. [Impact factor: 6.1]
  • Shelke V, Kale A, Dagar N, Habshi T, Gaikwad AB. (2023) Concomitant inhibition of TLR-4 and SGLT2 by phloretin and empagliflozin prevents diabetes-associated ischemic acute kidney injury. Food & Function. 14(11):5391-5403. [Impact factor: 6.1] 
  • Sankrityayan H, Shelke V, Kale A, Gaikwad AB. (2023) Evaluating the potential of tauroursodeoxycholic acid as add-on therapy in amelioration of streptozotocin-induced diabetic kidney disease. European Journal of Pharmacology 20:175528. [Impact factor: 5.0]
  • Kale AShelke V, Sankrityayan H, Dagar N, Gaikwad AB. (2022) Klotho restoration via ACE2 activation: A potential therapeutic strategy against acute kidney injury-diabetes comorbidity. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 166532. DOI: 10.1016/j.bbadis.2022.166532. [Impact factor: 6.2]
  • Sankrityayan H, Kale AShelke V, Gaikwad AB. (2022) Cyproheptadine, a SET7/9 inhibitor, reduces hyperglycaemia-induced ER stress alleviating inflammation and fibrosis in renal tubular epithelial cells. Archives of Physiology and Biochemistry 1:1-9. [Impact factor: 3.0]
  • Kale A, Sankrityayan H, Gaikwad AB. (2022) Epigenetic restoration of endogenous Klotho expression alleviates acute kidney injury-diabetes comorbidity. Life Sciences 288:120194 [Impact factor: 6.1]
  • Sankrityayan H, Kale A, Gaikwad AB. (2022) Inhibition of endoplasmic reticulum stress combined with activation of angiotensin-converting enzyme 2: Novel approach for the prevention of endothelial dysfunction in type 1 diabetic rats. Canadian Journal of Physiology and Pharmacology 100: 234-239. [Impact factor: 2.1] 
  • Sharma N, Gaikwad AB. (2020) Ameliorative effect of AT2R and ACE2 activation on ischemic renal injury associated cardiac and hepatic dysfunction. Environmental Toxicology and Pharmacology 80:103501. [Impact factor: 4.3]
  • Sharma N, Gaikwad AB. (2020) Effects of renal ischemia injury on brain in diabetic and non-diabetic rats: Role of angiotensin II type 2 receptor and angiotensin-converting enzyme 2. European Journal of Pharmacology 882:173241. [Impact factor: 5.0]
  • Sharma N, Sankrityayan H, Kale A, Gaikwad AB. (2020) Role of SET7/9 in the progression of ischemic renal injury in diabetic and non-diabetic rats. Biochemical and Biophysical Research Communications 12;528(1):14-20. [Impact factor: 3.1]
  • Sharma N, Malek V, Muley SR, Gaikwad AB., (2019), Angiotensin II type 2 receptor and angiotensin-converting enzyme 2 mediate ischemic renal injury in diabetic and non-diabetic rats, Life Sciences 235:116796. [Impact Factor: 6.1]
  • Malek V, Sharma N, Gaikwad AB., (2019), Simultaneous Inhibition of Neprilysin and Activation of ACE2 Prevented Diabetic Cardiomyopathy. Pharmacological Reports 71, 958–967. [Impact Factor: 4.4]
  • Malek V, Sharma N, Sankrityayan H, Gaikwad AB., (2019), Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy, Life Sciences 221 :159–167. [Impact Factor: 6.1]
  • Malek V, Sharma N, Gaikwad AB., (2019), Histone acetylation regulates natriuretic peptides and neprilysin gene expressions in diabetic cardiomyopathy and nephropathy, Current Molecular Pharmacology, 12 :61–71. [Impact factor: 2.7]
  • Malek V, Gaikwad AB., (2019) Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy, Cardiovascular Research 115(2):373-384. [Impact factor: 10.8]
  • Goru SK, Gaikwad AB. (2018) Novel reno-protective mechanism of Aspirin involves H2AK119 monoubiquitination and Set7 in preventing type 1 diabetic nephropathy. Pharmacological Reports 70:497–502. [Impact factor: 4.4]
  • Kadakol A, Malek V,Goru SK, Pandey A, Gaikwad AB. (2017) Telmisartan andesculetin combination ameliorates type 2 diabetic cardiomyopathy by reversal of H3, H2A, andH2B histone modifications. Indian Journal of Pharmacology 49(5):348-356. [Impact factor: 2.4]
  • Kadakol A, Goru SK,  Malek  V,  Gaikwad AB (2017) Esculetin ameliorates vascular perturbation by intervening in the occupancy of H2BK120Ub at At1, At2, Tgfβ1 and Mcp1 promoter gene in thoracic aorta of IR and T2D rats. Biomedicine & Pharmacotherapy  95: 1461–1468. [Impact factor: 7.5]
  • Goru SK, Kadakol A, Malek V, Pandey A, Sharma N, Gaikwad AB (2017) Diminazene aceturate prevents type 1 diabetic nephropathy through increasing glomerular ACE2 and AT2 receptor expression. British Journal of Pharmacology 174, 3118-3130. [Impact factor: 7.3]
  • Kadakol A, Malek V, Goru SK, Pandey A, Sharma N, Gaikwad AB (2017) Esculetin ameliorates insulin resistance and type 2 diabetic nephropathy through reversal of histone H3 acetylation and H2A lysine 119 monoubiquitination. Journal of Functional Foods 35, 256-266. [Impact factor: 5.6]
  • Pandey A, Gaikwad AB (2017) Compound 21 and Telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis. Biochemical and Biophysical Research Communications 487(4), 827–833. [Impact factor: 3.1]
  • Pandey A, Priyank R, Goru SK, Kadakol A, Malek V, Sharma N, Gaikwad AB (2017) Esculetin ameliorates hepatic fibrosis in high fat diet induced non-alcoholic fatty liver disease by regulation of FoxO1 mediated pathway. Pharmacological Reports 69(4), 666-672. [Impact factor: 4.4]
  • Pandey A, Goru SK, Kadakol A, Malek V, Sharma N, Gaikwad AB (2016) H2AK119 monoubiquitination regulates angiotensin II receptor mediated macrophage infiltration and renal fibrosis in type 2 diabetic rats. Biochimie. 131: 68-76. [Impact factor: 3.9]
  • Goru SK, Kadakol A, Pandey A, Malek V, Sharma N, Gaikwad AB (2016) Histone H2AK119 and H2BK120 Monoubiquitination Modulate SET7/9 and SUV39H1 in Type 1 Diabetes Induced Renal Fibrosis. Biochemical Journal 473(21):3937-3949 [Impact factor: 4.1]                                
  • Kadakol A, Pandey A, Goru SK, Malek V and Gaikwad AB (2015) Insulin Sensitizing and Cardioprotective Effects of Esculetin and Telmisartan combination by Attenuating Ang II Mediated Vascular Reactivity and Cardiac Fibrosis. European Journal of Pharmacology 765:591-7. [Impact factor: 5.0]
  • Pandey A, Goru SK, Kadakol A, Malek  V, and Gaikwad AB (2015) Differential Regulation of ACE2 and NF-κB by Ang II Receptor Subtypes in Type 2 Diabetic Kidney. Biochimie 118: 71-81. [Impact factor: 3.9]
  • Kadakol A, Malek V, Goru SK, Pandey A, and Gaikwad AB (2015) Esculetin Reverses Histone H2A/H2B Ubiquitination, H3 Dimethylation, Acetylation and Phosphorylation in preventing Type 2 Diabetic Cardiomyopathy. Journal of Functional Foods 17:127–136. [Impact factor: 5.6]
  • Kadakol A, Malek V, Goru SK, Pandey A, Bagal MB and Gaikwad AB (2015) Esculetin Attenuates Alterations in Ang II and Acetylcholine Mediated Vascular Reactivity Associated with Hyperinsulinemia and Hyperglycemia. Biochemical and Biophysical Research Communications 461(2), 342–347. [Impact factor: 3.1]
  • Kumar P, Prashanth KS, Gaikwad AB, Vij M, Barua CC, Bezbaruah B (2013) Disparity in actions of rosiglitazone against cisplatin-induced nephrotoxicity in female Sprague-Dawley rats. Environment Toxicology and Pharmacology 36(3):883-890. [Impact factor: 4.3]
  • Gaikwad AB, Gupta J, Tikoo K (2010) Epigenetic changes and alteration of Fbn1 and Col3A1 gene expression under hyperglycaemic and hyperinsulinaemic conditions. Biochemical Journal 432(2): 333- 341. [Impact factor: 4.1]
  • Gaikwad AB, Sayyed SG, Lichtnekert J, Tikoo K, Anders HJ (2010 ) Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy - related genes in type 2 diabetes. American Journal of Pathology 176(3): 1079- 1083. [Impact factor: 6.0]
  • Sayyed SG, Gaikwad AB, Lichtnekert J, Kulkarni O, Eulberg D, Klussmann S, Tikoo K, Anders HJ (2010) Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10. Nephrology Dialysis Transplantation 25(6): 1811- 1817. [Impact factor: 6.1]
  • Mulay SR, Gaikwad AB, Tikoo K (2010) Combination of aspirin with telmisartan suppresses the augmented TGFbeta/smad signaling during the development of streptozotocin- induced type I diabetic nephropathy. Chem Biol Interact 185(2): 137- 142. [Impact factor: 5.1]
  • Gupta J, Gaikwad AB, Tikoo, K (2010) Hepatic expression profiling shows involvement of PKC epsilon, DGK eta, Tnfaip, and Rho kinase in type 2 diabetic nephropathy rats. Journal of Cellular Biochemistry. 111(4): 944- 954. [Impact factor: 4.480]
  • Chandak PG, Gaikwad AB, Tikoo K (2009) Gallotannin ameliorates the development of streptozotocin- induced diabetic nephropathy by preventing the activation of PARP. Phytotherapy Research 23(1): 72- 77. [Impact factor: 7.2]
  • Pathan AR, Gaikwad AB, Viswanad B, Ramarao, P (2008) Rosiglitazone attenuates the cognitive deficits induced by high fat diet feeding in rats. European Journal of Pharmacology 589(1- 3): 176- 179. [Impact factor: 5.0]
  • Tikoo K, Meena RL, Kabra DG, Gaikwad AB (2008) Change in post - translational modifications of histone H3, heat - shock protein- 27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. British Journal of Pharmacology 153(6): 1225- 1231. [Impact factor: 7.3]
  • Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad AB (2008) Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radical Research 42(4): 397- 404. [Impact factor: 3.3]
  • Tikoo K, Tamta A, Ali IY, Gupta J, Gaikwad AB (2008) Tannic acid prevents azidothymidine (AZT) induced hepatotoxicity and genotoxicity along with change in expression of PARG and histone H3 acetylation. Toxicology Letters 177(2): 90- 96. [Impact factor: 3.5]
  • Gaikwad AB, Viswanad B, Ramarao P (2007) PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Pharmacological Research 55(5): 400- 407. [Impact factor: 9.3]
  • Tikoo K, Bhatt DK, Gaikwad AB, Sharma V, Kabra DG (2007) Differential effects of tannic acid on cisplatin induced nephrotoxicity in rats. FEBS Letters 581(10): 2027- 2035. [Impact Factor: 3.5]
  • Tikoo K, Tripathi DN, Kabra DG, Sharma V, Gaikwad AB (2007) Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53. FEBS Letters 581(5): 1071- 1078. [Impact Factor: 3.5]